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Abstract
Introduction: The mechanism of the cytotoxicity of anthracyclines is pleiotropic and its significance in cell growth inhibition
seems to be highly specific and dependent on cell type and anthracycline drug. Resistance and the high cardiotoxicity of
anthracyclines have stimulated many studies aimed at identifying critical substituents required for optimal activity. Many
authors point to the fact that the double-strand breaks, the consequence of the activity of topoisomerase II poisons, and the
inability of cells to repair the DNA lesions are the signal for apoptosis. The aim of this study was to define the influence of
4-demetoxy 2’-halogenated analogs with altered basicity at the 3’-position on topoisomerase II and the relationship of that
interaction with apoptosis and the cytotoxicity of these novel anthracyclines. Parental human ME18 melanoma cells and the
ME18/R subline, obtained experimentally, resistant to doxorubicin (DOX), exposed to 1.7 and 8.6 µM DOX or its analogs,
annamycin and WP903 (both 0.3 and 3.0 µM) were studied.
Materials and Methods: The MTT test was used to assay cytotoxicity. Interaction of the drugs with topoisomerase II and apop-
tosis were done by Western blot and fluorescence microscopy using Hoechst 33342.
Results: The structural changes at positions 4, 2’, and 3’ can influence topoisomerase II interaction and apoptotic activity,
although correlation between these events and cytotoxic consequences has not been proved. 
Conclusions: The biological response of the cells to the structurally similar anthracyclines may be variable and probably
depends on the cell type which seems to be an additional problem in the multifactorial resistance of tumor cells to anthra-
cyclines.
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SHORT COMMUNICATION
INTRODUCTION
The use of anthracyclines as antitumoral drugs dates
back to late 1960s and early 1970s. They are used in the
treatment of solid tumors, including breast cancer,
tumors of the bile ducts, uterus, esophagus, liver,
osteosarcomas, soft tissue sarcomas, as well as acute
myeloblastic leukemia [11]. The mechanism of the cyto-
toxicity of of anthracycline is pleiotropic and its signifi-
cance in cell growth inhibition seems to be highly spe-
cific, depending on cell type and the anthracycline drug.
It is still unknown which route of action is predominant
for drug resistance, which is a large obstacle in anthra-
cycline therapy. The most understood mechanism is that
related to transmembrane proteins, e.g. P-gp 170 or
MRP-1 or -2 overexpression, which results in the
decreased intracellular drug accumulation observed in
resistant cells. Also considered to be associated with the
development of drug resistance are changes in drug
metabolism, increased activity of detoxifying enzymes
such as glutathione transferase, peroxidase, and super-
oxide dismutase, alteration in topoisomerase II protein
levels, and DNA cleavage of that enzyme [22].
Topoisomerase II poisons such as doxorubicin
(DOX) or daunorubicin trap the cleavable complexestopoisomerase II-DNA and inhibit the resealing of
DNA breaks created by the enzyme. So-called “catalyt-
ic inhibitors”, such as aclarubicin, inhibit the
enzyme’s binding to its DNA substrate or lock the
homodimeric topoisomerase II in the form of a closed
bracelet surrounding DNA at the post-religation step,
like bisdioxopiperazine. But only topoisomerase II poi-
sons can generate DNA breaks [25]. The “topo II poi-
sons” are reported to be potentially more important and
possibly relevant mechanisms of resistance in cells that
may overexpress P-gp [12].
Many authors point to the fact that the double-
strand breaks, a consequence of the activity of topoiso-
merase II poisons, and the inability of the cells to repair
the DNA lesions are the signal for apoptosis [6, 8, 18, 19,
24]. On the basis of literature data it can be said that
tumors with higher apoptosis and topoisomerase II α
overexpression tend to be more responsive to anthracy-
clines [2, 20]. A number of studies have shown that the
profiles of topoisomerase II protein or gene expression
affect the response to anthracyclines [9, 16, 17]. The
observed link between topoisomerase II and clinical
response to anthracyclines-based chemotherapy implies
that topoisomerase II deserves further testing in
a prospective setting as a predictive marker [4, 21].
Although the topoisomerase II inhibitors have
a common intracellular target, the molecular basis of
their variable therapeutic efficacy is still not fully under-
stood [3]. Resistance and the multifactorial mechanism
of the cytotoxic action as well as the high cardiotoxicity
of anthracyclines have stimulated many studies aimed at
identifying critical substituents required for optimal
activity and, consequently, new anthracycline analogs
having better therapeutic index are being sought [3]. 
It was noted that topoisomerase II targeting or inter-
action with P-gp is related to the removal of a 4-metoxy
group and alteration of basicity at the 3’ position in the
DOX molecule [23, 26]. On the basis of a number of
studies it can be said that chemical modification makes
it possible to “select” mechanisms, for example to
reduce drug-P-gp interaction but maintain or increase
the desired cytotoxic action. In other words it is now
possible to design such “molecular switches” to influ-
ence their antitumoral efficacy.
As part of the collaboration with Prof. Waldemar
Priebe’s group at the University of Texas M.D.
Anderson Cancer Center, Houston, Texas, USA, the
anthracycline derivatives WP903 with Annamycin
(ANN), currently being evaluated in clinics in leukemia
patients, were chosen in screening studies as new
promising anticancer drugs (Fig.1). The aim of this
study was to define the influence of 4-demetoxy 2’-halo-
genated analogs with altered basicity at the 3’ position
on topoisomerase II and the relationship of that inter-
action with apoptosis and the cytotoxicity of these novel
anthracyclines. The stabilization of the complexes was
studied with Western blot (band depletion assay).
Apoptotic events were evaluated morphologically and in
PARP cleavage assay.
MATERIALS AND METHODS
Drugs
DOX was purchased from Fluka (Germany), and
WP903 and ANN were received from the University of
Texas M.D. Anderson Cancer Center, Houston, TX,
USA.
Cells
The ME18 human melanoma cell line was obtained
from the M. Sk³odowska-Curie Memorial Cancer
Center and Institute of Oncology, Warsaw, Poland.
ME18/R, an mdr-1-expressing subline resistant to DOX,
vinblastine, and methotrexate, was obtained experimen-
tally in our laboratory [1].
The cells were grown in Minimum Essential
Medium (MEM) supplemented with 10% fetal calf
serum and antibiotics (penicillin 10.000 u/ml, streptomy-
cin 10 mg/ml, amphotericin B, 0.9%). The ME18/R cells
were maintained in MEM with DOX 0.04 uM.
All cell cultures were mycoplasma free.
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Fig. 1. Structures of DOX and its analogs, ANN and WP903. 
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IMTT test
The test was performed as described in our previous
study [13]. The final concentrations of DOX, ANN, and
WP903 ranged from 0.09 to 10 µM. The cells were
exposed to the drugs for 48 h. In the further studies, all
the cell lines tested were exposed to the same drug con-
centrations.
Morphological evaluation
Twenty-four-hour cell cultures were exposed for 24
h to the drugs used at the concentrations of 1.7 and 8.6
µM DOX or 0.3 and 3.0 µM ANN or WP903. Apoptotic
symptoms such as chromatin condensation and apoptot-
ic bodies were observed in a fluorescence microscope
using Hoechst 33342. The procedure was described in
detail earlier [13].
Band depletion assay and apoptosis detection 
Twenty-four-hour cell cultures were exposed for 24
h to the drugs tested used at the above concentrations.
Nuclear extract preparation and Western blot analysis
were performed as previously described [13]. The bands
obtained were quantified using the Gel Doc 2000
System by BioRad with Quantity One 4.4.0 1-D Analysis
Software. For gel quantity evaluation, the bands of
interest were normalized to β-actin.
Statistical analysis
The statistical evaluation of the results was per-
formed using Student’s t-test and the Cochrane Cox test
for unrelated samples.
RESULTS AND DISCUSSION
The results obtained in this study indicate a lack of
correlation between the stabilization of cleavable com-
plexes, induction of apoptosis, and the cytotoxic activity
of the tested anthracyclines. DOX, the least cytotoxic
among the tested drugs (Table 1), stabilized the cleav-
able complexes in ME18 cells similarly to ANN, but
these comparable effects required an over twofold high-
er concentration of DOX (Fig. 2a, b). However, apop-
tosis, observed as PARP cleavage (Fig. 3a, b) and visible
through morphological symptoms (data not shown)
occurred only in ME18 cells exposed to ANN. None of
these effects were noted in ME18/R cells regardless of
the drug used.
WP903 was shown to be an apoptotic inducer of
ME18 and ME18/R cells (Fig. 3c). This was also con-
firmed in the microscopic analysis (data not shown).
Annexin V-FITC and the TUNEL tests yielded the
same results as those given in our earlier study [14].
That analog was noted as the most active cytotoxic drug
towards ME18/R cells (Table 1). In the light of the
study, the induction of apoptosis does not seem to be
related to stabilization of cleavable complexes, as pre-
sented in Fig. 2c.
The results obtained in this study are confirmed by
Gruber et al. [15] and Yamazaki et al. [27]. The authors
noted that the difference in drug sensitivity to DOX
might not be explainable by the topo II α levels. In turn,
Ramachandran et al. [24] noted that low DOX sensitiv-
ity of the human melanoma cell lines FCCM–9 and NH
was due to reduced DNA damage and low topo II activ-
ity. That dependence was also confirmed by De Graff et
al. [7], who observed that the non-toxic topo II inhibitor
WR-1065 protected Chinese hamster V79 cells against
DOX-induced cytotoxicity.
The results obtained here indicate that the cytotoxic
mechanisms of the anthracycline drug may be in part
related to apoptosis induction and may also depend on
the drug used. As shown, the stabilization of cleavable
complexes is not a condition sine qua non for apoptosis
induction. According to Li and Liu [19], the role of topo
II in mediating apoptosis may depend on the kind of lig-
ands participating in apoptotic induction. It is known
that apoptosis, which is a carefully regulated process of
cell death, may proceed through mechanisms which vary
according to the cell type [5, 10]. 
As shown, ANN and WP903 are clearly different
from DOX in evoking the stabilization of topoisomerase
II complexes and apoptosis, which proves the impor-
tance of the structural changes at the 4, 3’, and 2’ posi-
tions of the anthracycline molecule in the biological
activity of these drugs. The current results are in agree-
ment with those of Priebe [23] and Trevino et al. [26],
who indicated that the demetoxy analogs are more ac-
tive in trapping topoisomerase II cleavable complexes. 
It is interesting to note that the similar structural
changes, i.e. reduced basicity at 3’ and the removal of
the metoxy group at C4 of the aglycone as in ANN and
WP903, are supposed to be important only for the cyto-
toxic activity of WP903, but do not matter in the case of
ANN (Table 1).
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Table 1. IC50 values determined by the MTT test
Anthracycline ME18 ME18/R RFd
DOX 12.21±3.18a 48.68±2.06 4.0
ANN 0.90±0.17a, b 44.15±2.26 49.0
WP903 1.48±0.41a, b 5.41±0.43c 3.7
The cells were treated with the drugs, each used in the range
0.09–10 µM for 48 h, then the MTT test was done as
described earlier [13].
Results represent the mean ±SEM (n=8). 
a IC50 values (µM) statistically different from IC50 defined for
DOX, ANN, or WP903 in ME18/R cells (p<0.05).
b IC50 values statistically different from IC50 defined for DOX
in ME18 cells (p<0.05).
c IC50 value statistically different from IC50 defined for DOX
or ANN in ME18/R cells (p<0.05).
d Resistance factor (IC50ME18/R//IC50ME18).As Priebe [23] hypothesized, the 3’-amino group in
the anthracycline analogs is an important structural ele-
ment stabilizing the interaction of the drug with P-gp.
Our earlier studies using verapamil, probenecid, and
cyclosporine, the inhibitors of P-gp or MRP-1,2 trans-
membrane pumps, showed that these substances did not
significantly affect the intracellular WP903 concentra-
tion in ME18/R cells measured fluorometrically as
ng/106 cells at different time-points during incubation
with the drug or after removing medium with the drug
compared with cells untreated with inhibitors (data not
shown). The efflux of WP903 was observed at similar
levels in cells untreated or treated with transmembrane
protein inhibitors. This means that the increased cyto-
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Fig. 2. Topoisomerase II α band depletion assay. 24-h cell cultures
were treated for 24 h with: a – DOX (1.7 and 8.6 µM), b – ANN
(0.3 and 3.0 µM), or c – WP903 (0.3; 3.0 µM). Western blot analy-
sis was done with nuclear extracts according to the procedure
given in our previous study [11]. Results represent the mean
±SEM, n=3–4.
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Fig. 3. PARP cleavage induced by DOX (a); ANN (b); WP903 (c).
Light fields stand for PARP, 116 kDa; dark fields for PARP frag-
ments, 86 kDa. 24-h cell cultures were exposed for 24 h to the
drugs given in the concentrations: DOX (1.7 and 8.6 µM), ANN
and WP903 (both 0.3 and 3.0 µM). Western blot analysis was done
with nuclear extracts according to the procedures described in our
earlier study [11]. Results represent the mean ±SEM, n=3–4.
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Me18/R Me18toxicity of WP903 observed in ME18/R cells is probably
connected not only with a greater affinity of that drug to
the transmembrane proteins.
On the basis of these studies it can be said that the
mechanisms of action of anthracyclines are cell depen-
dent, which seems to be an additional problem in the
multifactorial resistance of tumor cells to anthracy-
clines.
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